头孢他定与二羟丙茶碱在4种输液中配伍后的稳定性

目的：考察室温下6h内头孢他定注射液与二羟丙茶碱注射液在4种输液中配伍后的稳定性。方法：采用双波长分光光度法测定各配伍液中头孢他定的含量变化情况。结果：室温下头孢他定注射液单独与4种输液配伍后6h降解1％以下,但头孢他定与二羟丙茶碱注射液配伍后室温下在4种输液中6h的降解程度与前者比较变化不大。结论：头孢他定注射液与二羟丙茶碱注射液配伍后在4种输液中6h内保持基本稳定。     

长春西汀与3种头孢类抗生素配伍的稳定性考察

目的:考察注射用长春西汀与头孢呋辛钠、头孢他啶和头孢曲松钠在9.0mg/mL氯化钠注射液中配伍的稳定性。方法:在25℃下,模拟临床用药,将长春西汀分别与头孢呋辛钠、头孢他啶和头孢曲松钠在9.0mg/mL氯化钠注射液中配伍,采用紫外分光光度法分别检测配伍液0~6h时质量浓度并观察其外观、pH值和不溶性微粒的变化。结果:3种配伍液在6h时长春西汀、头孢呋辛钠、头孢他啶和头孢曲松钠的质量浓度分别为0.0388mg/mL,7.6246mg/mL、7.7145mg/mL、9.5962mg/mL以及配伍液pH、外观无明显变化。结论:注射用长春西汀可以分别与头孢呋辛钠、头孢他啶,头孢曲松钠在9.0mg/mL氯化钠注射液中配伍,6h内是稳定的。     

注射用头孢噻肟钠与西咪替丁注射液在4种输液中配伍后的稳定性

目的：考察室温下6h内注射用头孢噻肟钠与西咪替丁注射液在4种输液（5％GS，10％GS，GNS，NS）中配伍后的稳定性。方法：采用一阶导数分光光度法和双波长光谱法测定各配伍液中头孢噻肟钠和西咪替丁的含量。结果：室温下注射用头孢噻肟钠或西咪替丁注射液单独与4种输液配伍后6h保持稳定；头孢噻肟钠与西咪替丁注射液配伍后，室温下头孢噻肟钠在4种输液中6h降解幅度＜2％，而西咪替丁＜3％。结论：注射用头孢噻肟钠与西咪替西注射液配伍后在4种输液中6h内保持稳定。     

替硝唑注射液与注射用头孢菌素的配伍稳定性考察

目的 研究替硝唑注射液与临床常用8种注射用头孢菌素配伍的稳定性.方法 分析替硝唑注射液与8种注射用头孢菌素在室温下配伍后的外观、pH值、微粒数、高效液相色谱峰.结果 替硝唑注射液与注射用头孢拉定、注射用头孢替唑钠、注射用头孢匹胺钠、注射用头孢曲松钠、注射头孢噻肟钠、注射用头孢吡肟配伍后无显著变化.结论 替硝唑注射液与注射用头孢哌酮钠在6h内可配伍使用,与注射用头孢呋辛钠在4h内可配伍使用,可与其他6种药物配伍使用.     

注射用卡络磺钠与4种常用输液的配伍稳定性

目的研究室温6 h内注射用卡络磺钠与5%葡萄糖注射液、10%葡萄糖注射液、0.9%氯化钠注射液和复方葡萄糖氯化钠注射液的配伍稳定性,为临床用药提供科学依据。方法采用紫外分光光度法和反相高效液相色谱法分别测定注射用卡络磺钠与上述4种输液配伍后,6 h内卡络磺钠的含量及有关物质,同时考察配伍液的外观和pH值。结果在室温条件下,注射用卡络磺钠与上述4种输液配伍6 h后,外观、pH值、含量和有关物质均无明显变化。结论注射用卡络磺钠可与上述4种注射液配伍使用。     

注射用甲磺酸帕珠沙星在不同输液中的稳定性考察

目的考察室温下6h内,注射用甲磺酸帕珠沙星与4种输液配伍的稳定性。方法采用紫外分光光度法测定配伍后0～6h内甲磺酸帕珠沙星的含量变化,同时观察外观及紫外吸收光谱的变化。结果室温下6h内甲磺酸帕珠沙星与4种输液配伍后外观、含量、紫外吸收光谱均无显著变化。结论室温下,6h内,注射用甲磺酸帕珠沙星可与4种输液配伍应用。     

注射用氨曲南与3种输液的配伍稳定性考察

目的:考察注射用氨曲南与果糖注射液、转化糖注射液和木糖醇注射液配伍后的稳定性,为糖尿病患者输液时溶媒的选择提供参考。方法:观察注射用氨曲南与3种输液配伍后在室温下6h内氨曲南的含量、微粒数量、溶液pH值及其他物理变化。结果:配伍液在6h内含量、pH值、微粒检查均符合要求。结论:注射用氨曲南在果糖注射液、转化糖注射液和木糖醇注射液中配伍稳定。     

注射用更昔洛韦与6种注射液的配伍稳定性的观察

目的 研究注射用更昔洛韦分别与浓氯化钠注射液、氯化钾注射液、注射用辅酶A、注射用三磷酸腺苷辅酶胰岛素、胞磷胆碱钠注射液、维生素B6注射液的配伍稳定性.方法 用分光光度法测定头孢曲松钠与6种药物配伍后4h内各药的含量,同时测定混合液的pH值,观察外观的变化.结果 4h内配伍基本稳定.结论 头孢曲松钠与6种药物配伍后,4h内其配合液各药含量、pH值及外观无显著变化.     

注射用维生素B_6与3种常用输液的配伍稳定性考察

目的:考察注射用维生素B6与5%葡萄糖注射液、0.9%氯化钠注射液和葡萄糖氯化钠注射液的配伍稳定性,为临床合理用药提供科学依据。方法:注射用维生素B6与3种输液配伍后,在室温6h内采用紫外分光光度法测定维生素B6与有关物质的含量,同时考察外观、pH值和6h时的高效液相色谱图。结果:在室温条件下,注射用维生素B6与上述3种输液配伍6h内,外观、pH值、含量和有关物质均无明显变化。结论:注射用维生素B6可与5%葡萄糖注射液、0.9%氯化钠注射液和葡萄糖氯化钠注射液配伍使用。     

注射用卡洛磺钠与3种药物配伍的稳定性考察

目的 研究注射用卡洛磺钠分别与注射用头孢曲松钠,维生素C注射液,氨甲苯酸注射液3种药物的配伍稳定性.方法 采用紫外分光光度法测定卡洛磺钠与3种药物配伍后6h内卡洛磺钠的含量变化,同时观察外观变化并测定pH值.结果 在室温25℃条件下,0～6h内配伍液外观、pH值、含量变化都没有明显变化.结论 在6h内卡洛磺钠与3种药物配伍基本稳定.本实验方法 简单、准确.     

Compatibility and stability of linezolid injection admixed with three cephalosporin antibiotics

OBJECTIVE: To evaluate the physical compatibility and chemical stability of linezolid (Zyvox-Pharmacia) 200 mg/100 mL admixed with cefazolin sodium 1 gram, ceftazidime 2 grams, and ceftriaxone sodium 1 gram for 7 days at 4 degrees C and 23 degrees C. DESIGN: Controlled experimental trial. SETTING: Laboratory. INTERVENTIONS: The test samples were prepared by adding the required amount of the cephalosporin antibiotic to bags of linezolid injection 200 mg/100 mL. MAIN OUTCOME MEASURES: Physical stability and chemical stability based on drug concentrations initially and after 1, 3, 5, and 7 days of storage at 4 degrees C and 23 degrees C protected from light. RESULTS: All of the linezolid admixtures with cephalosporins were clear when viewed in normal fluorescent room light and with a Tyndall beam. Measured turbidity and particulate content were low and exhibited little change. The cefazolin sodium-containing samples were colorless throughout the study. The admixtures with ceftazidime and ceftriaxone sodium had a slight yellow tinge initially, and the room temperature samples became a frank yellow color after 5 days. The refrigerated samples did not change color. High-performance liquid chromatography analysis found little or no loss of linezolid in any sample stored at either temperature throughout the study. Cefazolin sodium and ceftazidime in the linezolid admixtures at 4 degrees C remained stable for 7 days, but at 23 degrees C cefazolin sodium was stable for 3 days and ceftazidime for only 24 hours before cephalosporin decomposition exceeded 10%. Ceftriaxone sodium was less stable in the admixtures; 10% loss occurred in 3 days at 4 degrees C and more than 20% loss occurred in 24 hours at 23 degrees C. CONCLUSION: Admixtures of linezolid 200 mg/100 mL with cefazolin sodium 1 gram and ceftazidime 2 grams were physically compatible and chemically stable for at least 7 days stored at 4 degrees C protected from light and for 3 days and 1 day, respectively, at 23 degrees C protected from light. Admixtures of linezolid with ceftriaxone sodium 1 gram exhibited a rapid rate of cephalosporin loss at 23 degrees C, which precludes admixture of the two drugs.     

三种头孢类药物的输液稳定性影响因素研究

目的研究头孢呋辛钠、头孢曲松钠、头孢他啶三种头孢类药物的输液在5％葡萄糖注射液和0．9％氯化钠注射液中稳定性影响因素。方法在不同光照、不同温度以及不同时间条件下测定三种头孢类药物输液中药物的含量、pH值及不溶性微粒等。结果在不同光照和温度条件下,三种药物与两种输液配伍后3个小时以内含量基本稳定,头孢呋辛钠和头孢曲松钠在输液中的有关物质随着放置时间延长明显增加,头孢他啶相对不明显。结论三种头孢类药物与5％葡萄糖注射液和0．9％氯化钠注射液配伍在3个小时以内可以任意选择静脉滴注时间,但最好即配即用,其中头孢呋辛钠和头孢曲松钠最好避光滴注。在配药过程中,了解药物在输液中的稳定性影响因素有利于提高药物的临床疗效,促进合理用药。     

Stability of clindamycin phosphate with aztreonam, ceftazidime sodium, ceftriaxone sodium, or piperacillin sodium in two intravenous solutions

In admixtures containing clindamycin and either aztreonam, ceftazidime, ceftriaxone, or piperacillin in either 5% dextrose injection (D5W) or 0.9% sodium chloride injection (NS), the stability of each drug was studied. Each of the following combinations of drugs was added to 100-mL glass bottles of base solution: clindamycin phosphate 0.9 g and aztreonam 2.0 g, clindamycin phosphate 0.9 g and ceftazidime sodium 2.0 g, clindamycin phosphate 1.2 g and ceftriaxone sodium 2.0 g, and clindamycin phosphate 0.9 g and piperacillin sodium 4.0 g. Duplicate samples were prepared. Admixtures containing each single drug were also tested. Samples were visually inspected and tested for pH and drug concentration immediately after mixing and at 1, 4, 8, 12, 24, and 48 hours of storage in room temperature and light. Drug concentrations were determined by high-performance liquid chromatographic assay methods. Ceftriaxone retained greater than 90% of its original concentration for 24 hours in single-drug admixtures in NS, for eight hours with clindamycin in NS, and for one hour with clindamycin in D5W. Ceftazidime retained greater than 90% potency for 24 hours with clindamycin in D5W. In all other test admixtures, all drugs were stable for 48 hours. Under the conditions studied, clindamycin is compatible in the admixtures tested with aztreonam and piperacillin. Admixtures of clindamycin and ceftazidime in D5W should be used within 24 hours at room temperature. Clindamycin and ceftriaxone can be mixed in NS if administered within eight hours, but ceftriaxone is stable for only one hour in combination with clindamycin in D5W.     

Stability of ceftazidime and amino acids in parenteral nutrient solutions

The stability of ceftazidime was studied under conditions simulating administration via a Y-injection site into a primary infusion of parenteral nutrient (PN) solution; the stabilities of ceftazidime and amino acids when the drug was added directly to PN solutions were also studied. Three PN solutions containing 25% dextrose were used; the amino acid contents were 0, 2.5%, and 5%. Ceftazidime with sodium carbonate was used to prepare stock solutions of ceftazidime 40 mg/mL in both 0.9% sodium chloride injection and 5% dextrose injection; to simulate Y-site injection, samples were added to the three PN solutions to achieve ceftazidime concentrations of 10 and 20 mg/mL, or 1:1 and 1:3 ratios of drug solution to PN solution. Samples of these admixtures were assayed by high-performance liquid chromatography (HPLC) initially and after room-temperature (22 degrees C) storage for one and two hours. Additional solutions were prepared by adding sterile water for injection to ceftazidime with sodium carbonate; drug solutions were added to each PN solution in polyvinyl chloride bags to achieve ceftazidime concentrations of 1 and 6 mg/mL. The samples were assayed by HPLC for ceftazidime concentration after storage at 22 degrees C for 3, 6, 12, 24, and 36 hours and at 4 degrees C for 1, 3, 7, and 14 days. Amino acid stability was analyzed in admixtures containing 5% amino acids and ceftazidime 6 mg/mL after 24 and 48 hours at 22 degrees C and after 7 and 10 days at 4 degrees C.(ABSTRACT TRUNCATED AT 250 WORDS)     

三种头孢类药物的输液稳定性影响因素研究

目的：研究头孢呋辛钠、头孢曲松钠、头孢噻肟钠在0．9％氯化钠注射液和5％葡萄糖注射液中的稳定性影响因素。方法：在不同的温度（8、25、37℃）、不同光照（光照强度2500 lx、避光）及不同时间（0、0．5、1、2、3h）条件下测定三种头孢类药物输液中药物的含量、pH值和不溶性微粒等。结果：在不同温度和光照条件下,三种药物与两种输液配伍后3h内含量基本稳定,头孢呋辛钠和头孢曲松钠在输液中的有关物质随着放置时间延长明显增加,头孢噻肟钠相对不明显。结论：三种头孢类药物与0．9％氯化钠和5％葡萄糖配伍在3h以内可以任意选择静滴时间,但最好即配即用,其中头孢呋辛钠和头孢曲松钠最好避光滴注;熟悉药物在输液中的稳定性影响因素有利于提高药物的临床疗效,促进合理用药。     

13种儿科常用抗菌药物与小儿电解质补给注射液配伍稳定性

目的：探讨13种儿科常用抗菌药物与小儿电解质补给注射液的配伍稳定性。方法：模拟临床用药,考察13种儿科常用抗菌药物与小儿电解质补给注射液配伍后的外观、性状、pH和主要成分相对含量变化情况。结果：头孢呋辛钠、头孢他啶、头孢曲松钠、头孢美唑钠、哌拉西林钠/他唑巴坦钠、拉氧头孢钠、亚胺培南/西司他丁钠、美罗培南与小儿电解质补给注射液配伍后0~4 h内其外观、可见异物、pH和主要成分相对含量均无明显变化;万古霉素、阿奇霉素、阿米卡星、伏立康唑、头孢哌酮钠/舒巴坦钠与小儿电解质补给注射液配伍后0~8 h内其外观、性状、pH和主要成分相对含量均无明显变化。结论：头孢呋辛钠、头孢他啶、头孢曲松钠、头孢美唑钠、哌拉西林钠/他唑巴坦钠、拉氧头孢钠、亚胺培南/西司他丁钠、美罗培南、万古霉素、阿奇霉素、阿米卡星、伏立康唑、头孢哌酮钠/舒巴坦钠与小儿电解质补给注射液配伍良好     

莪术油葡萄糖注射液与5种抗生素的配伍稳定性

目的 :观察莪术油葡萄糖注射液与5种常用抗生素配伍后的稳定性。方法 :用紫外分光光度法测定莪术油葡萄糖注射液中主成分莪术醇3h内含量的变化 ,同时观察配伍溶液的外观并测定其pH值。结果 :莪术油葡萄糖注射液与5种抗生素配伍后 ,样品液均无气体或沉淀产生 ;pH值随加入药物的不同而不同 ,但在3h内均无明显改变。与头孢哌酮钠配伍后莪术醇的含量下降最大 ,样品液为棕色 ;与头孢曲松钠配伍后含量下降亦较明显 ;与头孢拉定配伍后含量下降6 % ;与奈替米星和克林霉素配伍后含量和颜色均无改变。结论 :本品可与奈替米星、克林霉素配伍 ,但不宜与头孢哌酮钠、头孢曲松钠和头孢拉定配伍应用     

注射用奥美拉唑钠与奥硝唑配伍稳定性的考察

目的:考察在避光条件下,温度分别为4、253、7℃的环境中6 h内注射用奥美拉唑钠与奥硝唑的配伍稳定性。方法:采用HPLC法测定配伍液在不同温度条件下放置6 h内不同时间点含量的变化,并观察其外观及测定pH值。结果:注射用奥美拉唑钠与奥硝唑配伍液在4、25、37℃的环境中6 h内,色泽和含量都有明显变化。结论:注射用奥美拉唑钠与奥硝唑不能配伍使用。